Corticosteroid Use in COPD Management

Introduction to Corticosteroid Therapy

The American Thoracic Society recommends that prednisone should not be used for long-term maintenance therapy in stable COPD, as it has no role in chronic management and the risks far outweigh any benefits 1, 2

Systemic corticosteroids, such as prednisone 30-40 mg orally once daily for 5 days, are the evidence-based standard for treating acute COPD exacerbations, according to the Global Initiative for Chronic Obstructive Lung Disease 3, 2
The European Respiratory Society states that systemic corticosteroids prevent hospitalization for subsequent exacerbations only within the first 30 days following the initial exacerbation 3, 2
Beyond 30 days, systemic corticosteroids should never be given for preventing exacerbations, as recommended by the American College of Chest Physicians with a Grade 1A recommendation (highest level of evidence) 2

The American College of Chest Physicians recommends using maintenance combination inhaled corticosteroid/long-acting β-agonist therapy, such as fluticasone/salmeterol, to prevent acute exacerbations in stable moderate to very severe COPD 1
This combination is superior to inhaled corticosteroid monotherapy and reduces exacerbation risk while minimizing systemic side effects, as stated by the National Institute for Health and Care Excellence 1

After completing a 5-day course of oral prednisone for an acute exacerbation, the Global Initiative for Chronic Obstructive Lung Disease recommends immediately initiating or optimizing inhaled corticosteroid/long-acting β-agonist combination therapy 3, 4
This maintains the improved lung function achieved during acute treatment and reduces relapse risk, according to the American Thoracic Society 3, 4

The American College of Chest Physicians advises never extending oral prednisone treatment beyond 5-7 days for a single exacerbation, as longer courses increase adverse effects without additional benefit 3, 2
A 5-day course is as effective as 10-14 day courses for improving lung function while minimizing side effects, as recommended by the European Respiratory Society 3
Oral prednisone is strongly preferred over intravenous corticosteroids, as stated by the National Institute for Health and Care Excellence, with a large observational study showing IV corticosteroids were associated with longer hospital stays and higher costs without clear benefit 3, 2

Hyperglycemia occurs with an odds ratio of 2.79, especially in diabetics, according to the American Diabetes Association 3
Weight gain, fluid retention, insomnia, and mood changes are common adverse effects of short-term corticosteroid use, as reported by the American College of Chest Physicians 3
Increased risk of gastrointestinal bleeding, particularly in patients with a history of GI bleeding or taking anticoagulants, is a potential adverse effect of short-term corticosteroid use, as warned by the European Respiratory Society 3